| Accession |
PRJCA011674 |
| Title |
An open, multicenter phase I clinical study of the safety, tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in patients with advanced solid tumors |
| Relevance |
Medical |
| Data types |
Clinical imaging metabolicGene biomarkersgene data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate the safety and tolerability of SHR-A2009 in patients with advanced solid tumors, and to provide the recommended dose for subsequent clinical studies (phase II clinical trial recommended dose, RP2D). |
| Sample scope |
Multiisolate |
| Release date |
2022-09-06 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Suzhou Shengdia Biomedical Co., LTD
|
NA
|
NA
|
|
|
|
| Submitter |
Jia
Ao
Pan (jiaao.pan@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2022-09-05 |
